These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36907635)

  • 21. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
    Herrera AF
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
    Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
    Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
    Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
    Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
    Onea AS; Jazirehi AR
    Am J Cancer Res; 2016; 6(2):403-24. PubMed ID: 27186412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
    Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T-cell therapy for B-cell lymphoma.
    Denlinger N; Bond D; Jaglowski S
    Curr Probl Cancer; 2022 Feb; 46(1):100826. PubMed ID: 35012754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
    Fu S; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy with drugs.
    Choi Y; Diefenbach CS
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):598-605. PubMed ID: 33275686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.
    Chen Z; Liu Y; Chen N; Xing H; Tian Z; Tang K; Rao Q; Xu Y; Wang Y; Wang M; Wang J
    Sci China Life Sci; 2023 Apr; 66(4):754-770. PubMed ID: 36251156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
    Zelenetz AD; Gordon LI; Chang JE; Christian B; Abramson JS; Advani RH; Bartlett NL; Budde LE; Caimi PF; De Vos S; Dholaria B; Fakhri B; Fayad LE; Glenn MJ; Habermann TM; Hernandez-Ilizaliturri F; Hsi E; Hu B; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Lim M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2021 Nov; 19(11):1218-1230. PubMed ID: 34781267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy.
    Zhou L; Li P; Ye S; Tang X; Wang J; Liu J; Liang A
    Front Med; 2020 Dec; 14(6):786-791. PubMed ID: 32789732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
    Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
    Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
    Front Immunol; 2021; 12():681984. PubMed ID: 34248965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
    Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
    J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.
    Alencar AJ; Hirayama AV; Clé DV; Salvino MA; Perini G; Arrais C; Baiocchi O; Palma LC; Colturato I; Vaz J; Chiattone R; de Lima M; Filho JS; Nabhan S; Rocha V; Guerino-Cunha RL; Chiattone CS
    Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S22-S29. PubMed ID: 34794792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma.
    Banerjee T; Vallurupalli A
    Curr Probl Cancer; 2022 Feb; 46(1):100825. PubMed ID: 35033383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Makita S; Yoshimura K; Tobinai K
    Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.